Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Camellia expects 2022 normality; Microsaic loss slims

Tue, 04th May 2021 18:13

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Camellia PLC - Kent-based agriculture and engineering services firm - Revenue for 2020 broadly steady at GBP291.2 million from GBP291.5 million in 2019, though pretax profit drops to GBP7.8 million from GBP22.3 million. Reports GBP8.2 million net charge resulting from legal and other expenses relating to the settlement of claims concerning its East African operations and largely pandemic-related impairment charges offset in part by gain on sale of Horizon farm property. Mainstains dividend at 144p. "While the UK is returning to normality to the benefit of some of our UK based businesses, we have concerns about further waves of the pandemic across India, Bangladesh and East Africa. We do not believe that normal trading conditions will emerge until 2022, and some businesses will continue to feel the effect of the pandemic for some time thereafter," Chair Malcolm Perkins says.

----------

Microsaic Systems PLC - micro-engineering, miniaturised chip-based mass spectrometry developer - Revenue for 2020 falls to GBP198,258 from GBP872,125, but pretax loss narrows to GBP2.6 million from GBP3.1 million. Total operating expenses fall to GBP2.7 million from GBP3.4 million. Says that while business is still affected by pandemic, first quarter of 2021 starts well with revenue of GBP145,000 versus just GBP52,000 the same period a year ago. "2020 was a difficult year for Microsaic, its employees and shareholders. Progress in the year to date shows us turning a corner, with Q1 revenues significantly above the same period last year, and with decent prospects indicating a sustained recovery," says Chief Executive Glenn Tracey. Separately on Tuesday, says it has signed non-binding heads of terms with a Chinese partner. The HoT describe the in-principle agreement for the parties to collaborate to supply and market Microsaic's micro-engineered MS technology for use within a point of care medical device monitoring system for hospital diagnostics in the Chinese market.

----------

Cardiff Property PLC - focuses in property investment and development in Thames Valley - Reports net asset value per share of GBP24.45 at March 31, up from GBP23.03 a year ago. Pretax profit falls to GBP365,000 from GBP387,000. Says Thames Valley property market continues to be affected by "strict" Covid-19 lockdown measures. "Working from home and the closure of many retail outlets has led to a marked reduction in letting and investment activity. Office rental levels within the Thames Valley experienced a decline as Landlords preferred to retain occupation of buildings. New lettings inevitably included incentives with shorter lease terms reflecting current uncertainty as to future occupation and trading," says Chair Richard Wollenberg.

----------

Frenkel Topping Group PLC - Manchester-based financial adviser and asset protection services - Revenue for 2020 rises to GBP10.1 million from GBP8.6 million in 2019, while pretax profit rises to GBP1.5 million from GBP1.2 million. Says 2020 was "another positive year" for the firm with results in line with board's expectations. Adds that first three months of 2020 have been strong. "The group has shown resilience against the continuing Covid-19 pandemic and alongside its 99% retention rates has a solid pipeline of new business opportunities that capitalise on the potential brought into the group by recent M&A activity," firm says, adding that it continues to trade in line with management expectations. Total dividend for 2020 is 1.36 pence, up 1% on 2019.

----------

BSF Enterprise PLC - UK-based company seeking acquisition target within the innovation marketing and technology sector - Reports operating loss of GBP31,858 for half-year to March 31, a touch narrower than GBP33,885 loss posted for year before. This is a direct result of administrative expenses slimming. Cash balance at year-end GBP407,050.

----------

Ethernity Networks Ltd - Israel-based networking and security solutions provider - Reports total funding inflows of over USD5.4 million since the beginning of December 2020 to date. "The significant boost to the company's cash reserves has supported the planned expansion of its R&D resources in order to meet the development requirements and to achieve the anticipated revenues for 2021," it says. Adds that 2021 revenue estimates remain in line with expectations, subject to product revenues recognition being dependent on the timely supply of FPGA components, cards and appliances. Notes there is currently a temporary worldwide component shortage that is affecting industry-wide customer deliverables, which Ethernity is overcoming through purchasing from parallel sources until supply levels recover from the original manufactures of the components.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives wholesale purchase order of EUR640,000 from European nutraceuticals producer and distributor, Swiss PharmaCan AG, for ArtemiC Rescue. This is the second wholesale purchase order received under the agreement with Swiss PharmaCan, with the original purchase order received in February. "Our team in Slovenia has been working tirelessly to ramp up production to ensure rapid deployment of this order, and any subsequent orders that may be received," says Roby Zomer, co-founder and managing director of MGC Pharma.

----------

Nightcap PLC - bar operator in the UK - Agrees to buy the Adventure Bar Group including +Venture Battersea Ltd, Adventure Bars Mid Ltd and Adventure Bars Luna Digbeth Ltd for a maximum of GBP2.5 million. The bars being acquired are seven established themed bars located in London locations, a large outdoor bar, food and entertainment venue in Birmingham, a bar site opening in Birmingham on May 17 and a 50% interest in a central London roof-top bar. The nine target bars include all of the bars branded 'Tonight Josephine', 'Bar Elba', 'Luna Springs' and 'Blame Gloria'. Proposes placing to raise around GBP4 million to partially repay debt which it will assume with deal, and to fund the UK roll out of the 'Tonight Josephine', 'Luna Springs' and 'Bar Elba' brands. Adds the five London Cocktail Club bars which opened on April 12 have traded well, and the remaining five scheduled to reopen on May 17 have seen encouraging levels of bookings.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.